[Histonet] RE: IHC antibody optimizing & validating

[Terri Braud]

Fortunately, they say nothing at all because if that were the case, they
would no longer be able to peddle their Proficiency Programs for IHC,
since those too, are fixed and processed elsewhere.  

Terri L. Braud, HT(ASCP)
Anatomic Pathology Supervisor
Holy Redeemer Hospital Laboratory
1648 Huntingdon Pike
Meadowbrook, PA 19046
Ph: 215-938-3676
Fax: 215-938-3874


-----Original Message-----
From: Cartun, Richard [mailto:Richard.Cartun <@t> hhchealth.org] 
Sent: Wednesday, March 26, 2014 11:47 AM
To: Terri Braud; histonet <@t> lists.utsouthwestern.edu
Subject: RE: IHC antibody optimizing & validating 

I have not read the entire document yet.  What do they say about using
tissues that have been fixed and processed elsewhere?

Richard

Richard W. Cartun, MS, PhD
Director, Histology & Immunopathology
Director, Biospecimen Collection Programs Assistant Director, Anatomic
Pathology Hartford Hospital
80 Seymour Street
Hartford, CT  06102
(860) 972-1596 Office
(860) 545-2204 Fax
richard.cartun <@t> hhchealth.org

-----Original Message-----
From: histonet-bounces <@t> lists.utsouthwestern.edu
[mailto:histonet-bounces <@t> lists.utsouthwestern.edu] On Behalf Of Terri
Braud
Sent: Tuesday, March 25, 2014 3:35 PM
To: histonet <@t> lists.utsouthwestern.edu
Subject: [Histonet] RE: IHC antibody optimizing & validating

CAP is very clear that in order to validate a new antibody, that: "once
the stain has been optimized, that for a well characterized antibody
with a limited spectrum of antigenic targets, like Chromogranin or PSA,
the validation can be limited.  A panel of 10 positive and 10 negative
neoplasms would be sufficient in this setting.  For an antibody that is
not well characterized and/or has a wide range of reported reactivity, a
more extensive validation is necessary.  The number of tissues tested
should in the circumstance be large enough to determine whether the
staining profile matches that previously described.  An exception to the
above requirements is that studies nay not be feasible for antigens such
as ALK that are only seen in rare tumors."
Thus sayeth CAP.
And if you're like me, I am not digging through all my cases to try to
come up with 30-40 neoplasms for each antibody, so I just order Tissue
Micro Arrays with the neoplasms I need.  20 positive and 20 negative
neoplastic tissues on one slide for easy staining and validation.  The
money you save on reagents to stain one little slide, more than makes up
for the cost of the slide.
I hope this helps.

Terri L. Braud, HT(ASCP)
---------------------------------------------------------------------------------



CONFIDENTIALITY NOTICE:

This E-Mail is intended only for the use of the individual or entity to which
it was sent. It may contain information that is privileged and/or confidential,
and the use or disclosure of such information may also be restricted under applicable
federal and state law. If you received this communication in error, please do not
distribute any part of it or retain any copies, and delete the original E-Mail.
Please notify the sender of any error by E-Mail.

Thank you for your cooperation.